FGF21 Extends Lifespan in Obese Mice Through Metabolic Gains Not Growth Changes
Adult-onset adipocyte FGF21 overexpression extends lifespan up to 3.3 years in high-fat-diet mice, cutting inflammation and toxic lipids.
Summary
Researchers engineered mice to overproduce FGF21 specifically in fat cells beginning in adulthood, then fed them a high-fat diet. These mice lived up to 3.3 years, resisted obesity, improved insulin sensitivity, and showed less liver fat. Crucially, benefits appeared without suppressing growth — ruling out a key confounding factor from earlier FGF21 studies. Aged transgenic mice also had fewer inflammatory immune cells and lower levels of ceramides, toxic lipid molecules, in visceral fat. Remarkably, these gains persisted even without adiponectin, suggesting FGF21 acts through additional pathways. The findings position adipose tissue as a central hub for FGF21's longevity effects and support its therapeutic potential for obesity-related aging diseases.
Detailed Summary
Obesity affects roughly 35% of U.S. adults over 65 and accelerates metabolic aging, making it a major driver of age-related disease. FGF21, a liver-derived hormone, has long been known to improve metabolism and extend lifespan in rodents, but prior overexpression models activated FGF21 from birth, confounding results with growth retardation and developmental changes. This study addressed that limitation by creating a novel mouse model with inducible, adipocyte-specific FGF21 overexpression that could be switched on only in adulthood.
Male mice with adult-onset adipocyte FGF21 overexpression were placed on a high-fat diet and monitored through natural death. Transgenic animals lived up to 3.3 years — a meaningful extension over controls — while resisting diet-induced weight gain, maintaining better insulin sensitivity, and developing significantly less hepatic steatosis. These metabolic benefits emerged without any reduction in body length or signs of growth suppression, confirming that FGF21's pro-longevity effects are separable from its known anti-growth actions.
In aged transgenic mice, visceral adipose tissue showed markedly lower levels of pro-inflammatory immune cells and reduced concentrations of ceramides — bioactive sphingolipids linked to insulin resistance, inflammation, and cellular stress. Because ceramide accumulation in fat is a hallmark of metabolic dysfunction in obesity, this finding points to lipotoxicity reduction as a key mechanism. Strikingly, when the researchers eliminated adiponectin — a fat-derived hormone previously thought to be required for ceramide clearance — the benefits of FGF21 overexpression persisted, indicating that FGF21 operates through adiponectin-independent pathways to reduce ceramide burden.
These results collectively establish adipose tissue as a primary site of FGF21 action for longevity under dietary stress. The study suggests that targeted delivery of FGF21 signaling to fat cells in adulthood could recapitulate the metabolic and lifespan benefits without developmental side effects, making it a more viable therapeutic strategy.
Caveats include the study's restriction to male mice, leaving sex-specific effects unexplored. The model also relies on supraphysiological FGF21 levels from transgenic overexpression, which may not fully mirror the pharmacological doses achievable in clinical settings. Nonetheless, the mechanistic clarity around ceramide reduction and inflammation in visceral fat offers actionable targets for drug development.
Key Findings
- Adult-onset adipocyte FGF21 overexpression extended lifespan up to 3.3 years in high-fat-diet male mice.
- Transgenic mice resisted obesity, improved insulin sensitivity, and showed reduced hepatic steatosis.
- Longevity benefits occurred without growth suppression, separating FGF21's metabolic from developmental effects.
- Aged transgenic mice had fewer visceral fat inflammatory immune cells and lower toxic ceramide levels.
- FGF21's ceramide-lowering and metabolic benefits persisted even in the absence of adiponectin.
Methodology
Researchers generated an inducible, adipocyte-specific FGF21 overexpression mouse model activated in adulthood to avoid developmental confounders. Male transgenic and control mice were fed a high-fat diet and followed to natural death for lifespan analysis, with metabolic phenotyping, lipidomics, and immune cell profiling performed at multiple time points.
Study Limitations
The study used only male mice, so whether findings apply to females is unknown. Transgenic overexpression produces supraphysiological FGF21 levels that may not reflect clinically achievable pharmacological doses. The specific downstream pathways mediating ceramide reduction independent of adiponectin remain to be fully characterized.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.